AIMS: Within the framework of the clinical development of BX471, this study was intended to provide experience in conducting 'thorough QT(c) studies' according to ICH E14. A broad range of QT correction methods and analysis strategies was employed. METHODS A double-blind, placebo- and positive-controlled, single-centre, three-way cross-over study was conducted in 74 healthy volunteers. Electrocardiograms were read by blinded experts. QT correction methods included Bazett's (QT(c)B), Fridericia's (QT(c)F) and several regression-based corrections. RESULTS: There was a significant QT(c)F prolongation of 10.26 ms by the positive control compared with placebo [95% confidence interval (7.83, 12.70)]. BX471 at therapeutic doses did not cause substantial QT(c) prolongation [QT(c)F estimate 2.93 ms, 95% confidence interval (1.00, 4.86); QT(c)B estimate 3.30 ms, 95% confidence interval (0.85, 5.74)]. Regression-based QT correction methods yielded similar results to Fridericia's correction [e.g. using a linear regression across the study population, QT(c) estimate 2.39 ms, 95% confidence interval (0.55, 4.23)]. Differences between the various regression-based correction methods were small. Results were not affected by whether the QT corrections were performed per ECG or per beat. CONCLUSIONS:BX471 does not cause meaningful QT(c) prolongation. Three QT correction methods may be sufficient in future studies: Bazett's (required by regulatory authorities), Fridericia's (as the most reliable fixed formula) and a regression-based correction (individually or population-based), each performed per ECG (i.e. applied to the means of several beats of one ECG recording).
RCT Entities:
AIMS: Within the framework of the clinical development of BX471, this study was intended to provide experience in conducting 'thorough QT(c) studies' according to ICH E14. A broad range of QT correction methods and analysis strategies was employed. METHODS A double-blind, placebo- and positive-controlled, single-centre, three-way cross-over study was conducted in 74 healthy volunteers. Electrocardiograms were read by blinded experts. QT correction methods included Bazett's (QT(c)B), Fridericia's (QT(c)F) and several regression-based corrections. RESULTS: There was a significant QT(c)F prolongation of 10.26 ms by the positive control compared with placebo [95% confidence interval (7.83, 12.70)]. BX471 at therapeutic doses did not cause substantial QT(c) prolongation [QT(c)F estimate 2.93 ms, 95% confidence interval (1.00, 4.86); QT(c)B estimate 3.30 ms, 95% confidence interval (0.85, 5.74)]. Regression-based QT correction methods yielded similar results to Fridericia's correction [e.g. using a linear regression across the study population, QT(c) estimate 2.39 ms, 95% confidence interval (0.55, 4.23)]. Differences between the various regression-based correction methods were small. Results were not affected by whether the QT corrections were performed per ECG or per beat. CONCLUSIONS:BX471 does not cause meaningful QT(c) prolongation. Three QT correction methods may be sufficient in future studies: Bazett's (required by regulatory authorities), Fridericia's (as the most reliable fixed formula) and a regression-based correction (individually or population-based), each performed per ECG (i.e. applied to the means of several beats of one ECG recording).
Authors: Gary J Noel; Jaya Natarajan; Shuchean Chien; Thomas L Hunt; Daniel B Goodman; Robert Abels Journal: Clin Pharmacol Ther Date: 2003-04 Impact factor: 6.875
Authors: Berit T Jensen; Charlotte E Larroude; Lars P Rasmussen; Niels-Henrik Holstein-Rathlou; Michael V Hojgaard; Erik Agner; Jørgen K Kanters Journal: Ann Noninvasive Electrocardiol Date: 2004-01 Impact factor: 1.468
Authors: Corina D Dota; Nils Edvardsson; Kajs-Marie Schützer; Eva Lavik Olofsson; Anders Malm; Tomas Morsing; Gunnar Fager Journal: Pacing Clin Electrophysiol Date: 2003-01 Impact factor: 1.976
Authors: M Liang; C Mallari; M Rosser; H P Ng; K May; S Monahan; J G Bauman; I Islam; A Ghannam; B Buckman; K Shaw; G P Wei; W Xu; Z Zhao; E Ho; J Shen; H Oanh; B Subramanyam; R Vergona; D Taub; L Dunning; S Harvey; R M Snider; J Hesselgesser; M M Morrissey; H D Perez Journal: J Biol Chem Date: 2000-06-23 Impact factor: 5.157
Authors: Velislav N Batchvarov; Azad Ghuran; Peter Smetana; Katerina Hnatkova; Monica Harries; Polychronis Dilaveris; A John Camm; Marek Malik Journal: Am J Physiol Heart Circ Physiol Date: 2002-06 Impact factor: 4.733
Authors: F Zipp; H P Hartung; J Hillert; S Schimrigk; C Trebst; M Stangel; C Infante-Duarte; P Jakobs; C Wolf; R Sandbrink; C Pohl; M Filippi Journal: Neurology Date: 2006-11-28 Impact factor: 9.910
Authors: Anne S Y Chain; Vincent F S Dubois; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua Journal: Br J Clin Pharmacol Date: 2013-11 Impact factor: 4.335